Cocrystal Pharma Inc reports results for the quarter ended September 30 - Earnings Summary

• Cocrystal Pharma Inc COCP.OQ reported a quarterly adjusted loss of 49 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of three analysts for the quarter was for a loss of 57 cents per share. Wall Street expected results to range from -59 cents to -55 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Cocrystal Pharma Inc's reported EPS for the quarter was a loss of 49 cents​.

• The company reported a quarterly loss of $4.94 million.

• Cocrystal Pharma Inc shares had held steady so far this quarter and gained 2.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 13.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cocrystal Pharma Inc is $7.00

This summary was machine generated from LSEG data November 13 at 03:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)